Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Famotidine  COVID-19 treatment studies for Famotidine  C19 studies: Famotidine  Famotidine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Loading...
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Famotidine for COVID-19: real-time meta analysis of 22 studies
Covid Analysis, May 22, 2022, DRAFT
https://c19early.com/fmmeta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Brennan (DB RCT) 48% 0.52 [0.20-1.32] no recov. 5/27 10/28 Improvement, RR [CI] Treatment Control Brennan (DB RCT) 43% 0.57 [0.21-1.55] no recov. 4/19 10/27 Brennan (DB RCT) 28% 0.72 [0.56-0.92] recov. time 27 (n) 28 (n) Shoaibi -3% 1.03 [0.89-1.18] death 1,816 (n) 26,820 (n) Shoaibi -3% 1.03 [0.92-1.15] death/ICU 1,816 (n) 26,820 (n) Zhou (PSM) -81% 1.81 [1.28-2.58] severe case 72/519 198/2,595 Yeramaneni -59% 1.59 [0.94-2.71] death 410 (n) 746 (n) Mura (PSM) 21% 0.79 [0.65-0.96] death 563 (n) 563 (n) Mura (PSM) 37% 0.63 [0.47-0.83] death 305 (n) 305 (n) Samim.. (SB RCT) 33% 0.67 [0.45-0.98] hosp. time 10 (n) 10 (n) Samim.. (SB RCT) 0% 1.00 [0.42-2.40] no recov. 5/10 5/10 Samim.. (SB RCT) 50% 0.50 [0.17-1.46] no recov. 3/10 6/10 Elhadi (ICU) 7% 0.93 [0.73-1.17] death 34/60 247/405 ICU patients Taşdemir 45% 0.55 [0.20-1.55] death 5/85 10/94 OT​1 Taşdemir 37% 0.63 [0.28-1.43] ICU 8/85 14/94 OT​1 Taşdemir 18% 0.82 [0.72-0.93] hosp. time 85 (n) 94 (n) OT​1 Taşdemir 20% 0.80 [0.65-0.99] recov. time 85 (n) 94 (n) OT​1 Kuno (PSM) 0% 1.00 [0.86-1.17] death 1,593 (n) 7,972 (n) Stolow -519% 6.19 [2.10-18.3] death 137 (n) 352 (n) Stolow -2390% 24.90 [3.70-168] ICU 137 (n) 352 (n) Wagner 70% 0.30 [0.20-0.44] death 638 (n) 819 (n) Pahwani (RCT) 11% 0.89 [0.36-2.20] death 8/89 9/89 Pahwani (RCT) 12% 0.88 [0.53-1.45] ventilation 21/89 24/89 Pahwani (RCT) 10% 0.90 [0.51-1.58] ICU 18/89 20/89 Pahwani (RCT) 17% 0.83 [0.79-0.89] hosp. time 89 (n) 89 (n) Pahwani (RCT) 10% 0.90 [0.85-0.96] recov. time 89 (n) 89 (n) Siraj 36% 0.64 [0.48-0.83] death 183/711 122/289 Freedberg (PSM) 57% 0.43 [0.21-0.86] death/int. 8/84 332/1,536 Mather (PSM) 61% 0.39 [0.20-0.74] death 83 (n) 689 (n) Mather (PSM) 50% 0.49 [0.31-0.79] death/int. 83 (n) 689 (n) Balouch 22% 0.78 [0.36-1.51] symp. case 18/80 49/227 Balouch 37% 0.63 [0.26-1.54] recov. time 80 (n) 227 (n) Yeramaneni 51% 0.49 [0.16-1.52] death 351 (n) 6,807 (n) Cheung -34% 1.34 [0.24-6.06] severe case 23 (n) 929 (n) Fung 0% 1.00 [0.96-1.04] death population-based cohort Fung 6% 0.94 [0.91-0.97] hosp. population-based cohort Fung -12% 1.12 [1.10-1.15] cases population-based cohort Razjouyan 27% 0.73 [0.59-0.92] death 93 (n) 9,981 (n) Wallace -11% 1.11 [0.89-1.35] death 98/423 1,436/7,521 MacFadden 7% 0.93 [0.84-1.03] cases n/a n/a famotidine COVID-19 outcomes c19early.com/fm May 2022 1 OT: comparison with other treatment Favors famotidine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit